

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_77928
Title of the Manuscript:	ANTIOXIDANT AND ANTI INFLAMMATORY ACTIVITY OF COPPER NANOPARTICLES SYNTHESIZED USING RED TEA
Type of the Article	Research paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ul style="list-style-type: none"> ✓ In title authors mentioned nanoparticles as copper but in discussion, authors have mentioned nanoparticles as ZnO in one place and CuO in another place. Why is there so much confusion? ✓ In 2.2. Synthesis of nanoparticles: The volume of CuSO₄ is not given. ✓ Authors mentioned about measurement of absorbance by UV - Visible Spectrometer, but it is not given and explained. ✓ Authors should confirm the formation of ZnO nanoparticles by any characterization tools like UV –Visible spectroscopy, FTIR and XRD. ✓ Authors should calculate and mention the particle size and shape of the nanoparticle by XRD, SEM / TEM / AFM, etc. 	<p>Correction made</p> <p>Done revision</p> <p>Corrected</p>
Minor REVISION comments	<ul style="list-style-type: none"> ✓ Edit the manuscript as per the guidelines given in the below link http://peerreviewcentral.com/page/general-guideline-for-authors For example; The reference style is not consistent. ✓ DPPH full form is wrongly mentioned. ✓ When mentioning reference numbers (5) (6), authors should mention it as (5, 6) ✓ When mentioning reference numbers (17–29),(30–34) (35) (36), authors should mention it as (17- 36) ✓ When writing a conclusion, there is no need for any references. ✓ CuSO₄ should be written like CuSO₄ (4 in subscript). ✓ HCL should be written like HCl. ✓ TiO₂ should be written like TiO₂ (2 in subscript). ✓ In the introduction part, the word nan-oparticles should be corrected as nanoparticles. ✓ Irrelevant references (17-36) are given in the introduction part. ✓ The below equation $\% \text{ Inhibition} = \text{Control O.D} - \text{Sample O.D} / \text{Control O.D}$ should be mentioned like this $\% \text{ Inhibition} = (\text{Control O.D} - \text{Sample O.D}) / \text{Control O.D}$ 	<p>Revised</p> <p>Corrected</p> <p>Revised as suggested</p>
Optional/General comments	If possible give reasons for the anti-inflammatory and antioxidant activity of CuO nanoparticles	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	